Acute myeloid leukemia targeted drug ivonib

Ivosidenib, trade name Tosovo, is an acute myeloid leukemia (AML) targeted drug that has attracted much attention in recent years. As China's first approved potent oral targeted inhibitor for isocitrate dehydrogenase-1 (IDH1) mutant cancer, ivosidenib provides a new treatment option for AML patients.

Avosidenib was originally developed byAgios Pharmaceuticals. In 2018, CStone Pharmaceuticals and Agios reached an exclusive agreement for development and commercialization in Greater China. Since then, the clinical development and commercialization authorization area of u200bu200bthe drug has been expanded from Greater China to Singapore. After rigorous clinical trials and evaluations, on February 9, 2022, China China's National Medical Products Administration (NMPA) approved ivonib's new drug marketing application, making it the first approved IDH1 inhibitor in China.

Avosidenib is mainly used to treat adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) who carry IDH1 susceptibility mutations. In addition, it received FDA approval in the United States for the treatment of newly diagnosed AML patients with IDH1 mutations, who are typically 75 years or older or have comorbidities that preclude intensive induction chemotherapy. Ivonib reduces the level of 2-HGhydroxyglutarate (2-HG) in tumor cells by inhibiting the activity of mutated IDH1enzyme, thereby restoring the normal epigenetic state, promoting the differentiation of medulloblasts into mature blood cells, and inhibiting the development of leukemia.

The recommended dose of ivonib is 500 mg once daily, which can be taken orally on an empty stomach or after a meal. Patients should avoid taking it with fatty foods and swallow the tablets whole. During the treatment process, blood cell counts and blood biochemical indicators need to be monitored regularly to ensure patient safety.